BACKGROUND: Sexually transmitted infections (STIs) are associated with an increased risk of human immunodeficiency virus (HIV) infection, but their biological effect on HIV susceptibility is not fully understood. METHODS: Female pig-tailed macaques inoculated with Chlamydia trachomatis and Trichomonas vaginalis (n = 9) or medium (controls; n = 7) were repeatedly challenged intravaginally with SHIVSF162p3. Virus levels were evaluated by real-time polymerase chain reaction, plasma and genital cytokine levels by Luminex assays, and STI clinical signs by colposcopy. RESULTS: Simian/HIV (SHIV) susceptibility was enhanced in STI-positive macaques (P = .04, by the log-rank test; relative risk, 2.5 [95% confidence interval, 1.1-5.6]). All STI-positive macaques were SHIV infected, whereas 3 controls (43%) remained uninfected. Moreover, relative to STI-negative animals, SHIV infections occurred earlier in the menstrual cycle in STI-positive macaques (P = .01, by the Wilcoxon test). Levels of inflammatory cytokines (interferon γ, interleukin 6, and granulocyte colony-stimulating factor [G-CSF]) were higher in STI-positive macaques during STI inoculation and SHIV exposure periods (P ≤ .05, by the Wilcoxon test). CONCLUSIONS: C. trachomatis and T. vaginalis infection increase the susceptibility to SHIV, likely because of prolonged genital tract inflammation. These novel data demonstrate a biological link between these nonulcerative STIs and the risk of SHIV infection, supporting epidemiological associations of HIV and STIs. This study establishes a macaque model for studies of high-risk HIV transmission and prevention. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Sexually transmitted infections (STIs) are associated with an increased risk of human immunodeficiency virus (HIV) infection, but their biological effect on HIV susceptibility is not fully understood. METHODS: Female pig-tailed macaques inoculated with Chlamydia trachomatis and Trichomonas vaginalis (n = 9) or medium (controls; n = 7) were repeatedly challenged intravaginally with SHIVSF162p3. Virus levels were evaluated by real-time polymerase chain reaction, plasma and genital cytokine levels by Luminex assays, and STI clinical signs by colposcopy. RESULTS: Simian/HIV (SHIV) susceptibility was enhanced in STI-positive macaques (P = .04, by the log-rank test; relative risk, 2.5 [95% confidence interval, 1.1-5.6]). All STI-positive macaques were SHIV infected, whereas 3 controls (43%) remained uninfected. Moreover, relative to STI-negative animals, SHIV infections occurred earlier in the menstrual cycle in STI-positive macaques (P = .01, by the Wilcoxon test). Levels of inflammatory cytokines (interferon γ, interleukin 6, and granulocyte colony-stimulating factor [G-CSF]) were higher in STI-positive macaques during STI inoculation and SHIV exposure periods (P ≤ .05, by the Wilcoxon test). CONCLUSIONS:C. trachomatis and T. vaginalis infection increase the susceptibility to SHIV, likely because of prolonged genital tract inflammation. These novel data demonstrate a biological link between these nonulcerative STIs and the risk of SHIV infection, supporting epidemiological associations of HIV and STIs. This study establishes a macaque model for studies of high-risk HIV transmission and prevention. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
Chlamydia; HIV risk; HIV susceptibility model; STI or STD; Trichomonas; macaque; menstrual cycle
Authors: R H Gray; M J Wawer; N K Sewankambo; D Serwadda; C Li; L H Moulton; T Lutalo; F Wabwire-Mangen; M P Meehan; S Ahmed; L A Paxton; N Kiwanuka; F Nalugoda; E L Korenromp; T C Quinn Journal: AIDS Date: 1999-10-22 Impact factor: 4.177
Authors: M Laga; A Manoka; M Kivuvu; B Malele; M Tuliza; N Nzila; J Goeman; F Behets; V Batter; M Alary Journal: AIDS Date: 1993-01 Impact factor: 4.177
Authors: E C Breen; A R Rezai; K Nakajima; G N Beall; R T Mitsuyasu; T Hirano; T Kishimoto; O Martinez-Maza Journal: J Immunol Date: 1990-01-15 Impact factor: 5.422
Authors: F A Plummer; J N Simonsen; D W Cameron; J O Ndinya-Achola; J K Kreiss; M N Gakinya; P Waiyaki; M Cheang; P Piot; A R Ronald Journal: J Infect Dis Date: 1991-02 Impact factor: 5.226
Authors: G Poli; P Bressler; A Kinter; E Duh; W C Timmer; A Rabson; J S Justement; S Stanley; A S Fauci Journal: J Exp Med Date: 1990-07-01 Impact factor: 14.307
Authors: Katherine Butler; Jana M Ritter; Shanon Ellis; Monica R Morris; Debra L Hanson; Janet M McNicholl; Ellen N Kersh Journal: J Acquir Immune Defic Syndr Date: 2016-08-01 Impact factor: 3.731
Authors: Sundaram Ajay Vishwanathan; Rachael D Aubert; Monica R Morris; Chunxia Zhao; Christi Philips; George M Khalil; Frank Deyounks; Kristen Kelley; Jana M Ritter; C Y Chen; Ellen N Kersh; Janet M McNicholl Journal: Sex Transm Dis Date: 2017-09 Impact factor: 2.830
Authors: Kelly B Arnold; Adam Burgener; Kenzie Birse; Laura Romas; Laura J Dunphy; Kamnoosh Shahabi; Max Abou; Garrett R Westmacott; Stuart McCorrister; Jessie Kwatampora; Billy Nyanga; Joshua Kimani; Lindi Masson; Lenine J Liebenberg; Salim S Abdool Karim; Jo-Ann S Passmore; Douglas A Lauffenburger; Rupert Kaul; Lyle R McKinnon Journal: Mucosal Immunol Date: 2015-06-24 Impact factor: 7.313
Authors: S A Vishwanathan; A Burgener; S E Bosinger; G K Tharp; P C Guenthner; N B Patel; K Birse; D L Hanson; G R Westmacott; T R Henning; J Radzio; J G Garcia-Lerma; T B Ball; J M McNicholl; E N Kersh Journal: J Virol Date: 2015-06-24 Impact factor: 5.103
Authors: Ellen N Kersh; Tara R Henning; Charles Dobard; Walid Heneine; Janet M McNicholl Journal: AIDS Res Hum Retroviruses Date: 2015-08-06 Impact factor: 2.205